Stocklytics Platform
Asset logo for symbol DSGN
Design Therapeutics
DSGN43
$3.80arrow_drop_down1.03%-$0.04
Penny Stock
Asset logo for symbol DSGN
DSGN43

$3.80

arrow_drop_down1.03%

Performance History

Chart placeholder
Key Stats
Open$3.71
Prev. Close$3.87
EPS-0.85
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$190.74M
PE Ratio-
LOWHIGH
Day Range3.71
3.94
52 Week Range1.94
7.74
Ratios
Revenue-
EBITDA Margin %-
EPS-0.85

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Design Therapeutics (DSGN)

Design Therapeutics, Inc. (DSGN) is a biotechnology company focused on developing gene-editing therapies for the treatment of serious genetic disorders. The company's mission is to harness the power of CRISPR technology to correct disease-causing mutations at the DNA level, offering hope to patients with limited treatment options.
DSGN's lead program targets the genetic cause of Friedreich's ataxia (FA), a debilitating neurodegenerative disorder. By restoring the expression of the frataxin protein, which is deficient in FA patients, the company aims to slow or halt the progression of the disease. This has the potential to significantly improve the lives of FA patients and their families.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. João Siffert M.D.
Headquarters
Carlsbad
Employees
68
Exchange
NASDAQ
add Design Therapeutics to watchlist

Keep an eye on Design Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Design Therapeutics's (DSGN) price per share?

The current price per share for Design Therapeutics (DSGN) is $3.81. The stock has seen a price change of -$0.04 recently, indicating a -1.03% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Design Therapeutics (DSGN)?

For Design Therapeutics (DSGN), the 52-week high is $7.75, which is 103.55% from the current price. The 52-week low is $1.94, the current price is 96.03% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Design Therapeutics (DSGN) a growth stock?

Design Therapeutics (DSGN) has shown an average price growth of -1.65% over the past three years. It has received a score of 25 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Design Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Design Therapeutics (DSGN) stock price performance year to date (YTD)?

As of the latest data, Design Therapeutics (DSGN) has a year-to-date price change of -38.33%. Over the past month, the stock has experienced a price change of -3.91%. Over the last three months, the change has been -20.73%. Over the past six months, the figure is -32.3%.
help

Is Design Therapeutics (DSGN) a profitable company?

Design Therapeutics (DSGN) has a net income of -$66.86M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$78.19M. Furthermore, the EBITDA is -$60.22M.
help

What is the market capitalization of Design Therapeutics (DSGN)?

Design Therapeutics (DSGN) has a market capitalization of $190.74M. The average daily trading volume is 3.82, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level